FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328117183> ?p ?o ?g. }

• W4328117183 abstract "Objective To analyze the efficacy of mycophenolate mofetil (MMF) and glucocorticoid administration in patients with thyroid-associated ophthalmopathy (TAO). Methods Sixty patients with moderate to severe TAO treated in Jingzhou Central Hospital from January 2022 to June 2022 were selected and enrtolled in this study. The subjects were divided into experimental group (n=30) and control group (n=30) based on the random number table method. Glucocorticoid pulse therapy was provided in the control group, while MMF was given in the experimental group on the basis of Control group. Clinical activity score (CAS), quality of life (QOL), visual acuity, eyelid fissure width, intraocular pressure, and degree of exophthalmos were observed at the time of admission and at the 12 th week and 24 th post-treatment weeks. We compared the immune function (TRAb, IL-6, and CD4+/CD8+) of the two groups pre-treatment and 24 weeks post-treatment, and evaluated the clinical therapeutic effect. Results The clinical effective rates at 12 and 24 weeks in the experimental group were higher (73.3% and 83.3%) than those in the control group (46.7% and 60.0%) ( P &lt; 0.05). After 12 weeks of treatment, patients’ CAS scores, and bilateral lid fissure width decreased and right eye visual acuity increased in the control group compared with those before treatment ( P &lt; 0.05); further, after 24 weeks of treatment, patients’ QOL scores and bilateral visual acuity increased and CAS scores, bilateral lid fissure width and proptosis decreased compared with those before treatment, and patients’ QOL scores, CAS scores and bilateral proptosis improved more than those at 12 weeks of treatment ( P &lt; 0.05). Additionally, greater improvements were observed in the patients’ QOL and CAS scores, and proptosis after 24-week treatment than after 12-week treatment ( P &lt;0.05). In the experimental group, the QOL score and binocular visual acuity increased, whereas the CAS score, intraocular pressure, lid width, and proptosis decreased after 12 weeks of treatment as compared to the values of these parameters in the pre-treatment period ( P &lt; 0.05); after 24 weeks of treatment, greater improvements were established in the ocular-related indexes improved compared to the pre-treatment period and after 12 weeks of treatment ( P &lt; 0.05). After 12 weeks of treatment, the patients in the experimental group had more considerable improvements in the right visual acuity, right intraocular pressure, and left lid fissure width than the control group ( P &lt; 0.05); at 24 weeks of treatment, patients in the experimental group had greater improvements in the QOL score, bilateral visual acuity, intraocular pressure, bilateral lid fissure width, and bilateral proptosis than the control group ( P &lt; 0.05). No significant differences were found in the values of TRAb, IL-6, and CD4+/CD8+ between the two groups before treatment ( P &gt;0.05); the values of TRAb, IL-6, and CD4+/CD8+ in the experimental group was significantly lower than those before treatment and in the control group after 24weeks of treatment. ( P &gt;0.05). No statistically significant difference was observed in the incidence of liver damage and menstrual disorders between the two groups during the 24 weeks of treatment ( P &gt;0.05). Conclusion The combination of oral MMF and glucocorticoid shock therapy is an effective drug for the treatment of patients with moderately active TAO." @default.
• W4328117183 created "2023-03-22" @default.
• W4328117183 creator A5008294531 @default.
• W4328117183 creator A5012374676 @default.
• W4328117183 creator A5033020983 @default.
• W4328117183 creator A5053783706 @default.
• W4328117183 creator A5055977589 @default.
• W4328117183 creator A5067681000 @default.
• W4328117183 date "2023-03-21" @default.
• W4328117183 modified "2023-09-25" @default.
• W4328117183 title "Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients" @default.
• W4328117183 cites W2010996456 @default.
• W4328117183 cites W2024125916 @default.
• W4328117183 cites W2163721408 @default.
• W4328117183 cites W2220890392 @default.
• W4328117183 cites W2288910126 @default.
• W4328117183 cites W2786397131 @default.
• W4328117183 cites W3107470055 @default.
• W4328117183 cites W4294992105 @default.
• W4328117183 doi "https://doi.org/10.3389/fendo.2023.1140196" @default.
• W4328117183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37025403" @default.
• W4328117183 hasPublicationYear "2023" @default.
• W4328117183 type Work @default.
• W4328117183 citedByCount "0" @default.
• W4328117183 crossrefType "journal-article" @default.
• W4328117183 hasAuthorship W4328117183A5008294531 @default.
• W4328117183 hasAuthorship W4328117183A5012374676 @default.
• W4328117183 hasAuthorship W4328117183A5033020983 @default.
• W4328117183 hasAuthorship W4328117183A5053783706 @default.
• W4328117183 hasAuthorship W4328117183A5055977589 @default.
• W4328117183 hasAuthorship W4328117183A5067681000 @default.
• W4328117183 hasBestOaLocation W43281171831 @default.
• W4328117183 hasConcept C102652120 @default.
• W4328117183 hasConcept C126322002 @default.
• W4328117183 hasConcept C126894567 @default.
• W4328117183 hasConcept C141071460 @default.
• W4328117183 hasConcept C2778257484 @default.
• W4328117183 hasConcept C2780841215 @default.
• W4328117183 hasConcept C2781092963 @default.
• W4328117183 hasConcept C2993291352 @default.
• W4328117183 hasConcept C526584372 @default.
• W4328117183 hasConcept C71924100 @default.
• W4328117183 hasConceptScore W4328117183C102652120 @default.
• W4328117183 hasConceptScore W4328117183C126322002 @default.
• W4328117183 hasConceptScore W4328117183C126894567 @default.
• W4328117183 hasConceptScore W4328117183C141071460 @default.
• W4328117183 hasConceptScore W4328117183C2778257484 @default.
• W4328117183 hasConceptScore W4328117183C2780841215 @default.
• W4328117183 hasConceptScore W4328117183C2781092963 @default.
• W4328117183 hasConceptScore W4328117183C2993291352 @default.
• W4328117183 hasConceptScore W4328117183C526584372 @default.
• W4328117183 hasConceptScore W4328117183C71924100 @default.
• W4328117183 hasLocation W43281171831 @default.
• W4328117183 hasLocation W43281171832 @default.
• W4328117183 hasLocation W43281171833 @default.
• W4328117183 hasOpenAccess W4328117183 @default.
• W4328117183 hasPrimaryLocation W43281171831 @default.
• W4328117183 hasRelatedWork W113810927 @default.
• W4328117183 hasRelatedWork W1586374228 @default.
• W4328117183 hasRelatedWork W2003938723 @default.
• W4328117183 hasRelatedWork W2047967234 @default.
• W4328117183 hasRelatedWork W2118496982 @default.
• W4328117183 hasRelatedWork W2364998975 @default.
• W4328117183 hasRelatedWork W2369162477 @default.
• W4328117183 hasRelatedWork W2439875401 @default.
• W4328117183 hasRelatedWork W4238867864 @default.
• W4328117183 hasRelatedWork W2525756941 @default.
• W4328117183 hasVolume "14" @default.
• W4328117183 isParatext "false" @default.
• W4328117183 isRetracted "false" @default.
• W4328117183 workType "article" @default.